- Home
- CRDL vs PGP Comparison
CRDL vs PGP Comparison
Compare CRDL & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- PGP
- Stock Information
- Founded
- CRDL 2017
- PGP 2003
- Country
- CRDL Canada
- PGP United States
- Employees
- CRDL N/A
- PGP N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- PGP Finance Companies
- Sector
- CRDL Health Care
- PGP Finance
- Exchange
- CRDL Nasdaq
- PGP Nasdaq
- Market Cap
- CRDL 90.4M
- PGP 97.1M
- IPO Year
- CRDL N/A
- PGP N/A
- Fundamental
- Price
- CRDL $1.22
- PGP $8.53
- Analyst Decision
- CRDL Strong Buy
- PGP
- Analyst Count
- CRDL 2
- PGP 0
- Target Price
- CRDL $9.00
- PGP N/A
- AVG Volume (30 Days)
- CRDL 859.1K
- PGP 39.8K
- Earning Date
- CRDL 11-13-2025
- PGP 01-01-0001
- Dividend Yield
- CRDL N/A
- PGP 10.84%
- EPS Growth
- CRDL N/A
- PGP N/A
- EPS
- CRDL N/A
- PGP N/A
- Revenue
- CRDL N/A
- PGP N/A
- Revenue This Year
- CRDL N/A
- PGP N/A
- Revenue Next Year
- CRDL N/A
- PGP N/A
- P/E Ratio
- CRDL N/A
- PGP N/A
- Revenue Growth
- CRDL N/A
- PGP N/A
- 52 Week Low
- CRDL $0.77
- PGP $5.83
- 52 Week High
- CRDL $2.24
- PGP $7.81
- Technical
- Relative Strength Index (RSI)
- CRDL 63.48
- PGP 51.68
- Support Level
- CRDL $1.01
- PGP $8.13
- Resistance Level
- CRDL $1.38
- PGP $8.54
- Average True Range (ATR)
- CRDL 0.08
- PGP 0.13
- MACD
- CRDL 0.02
- PGP -0.01
- Stochastic Oscillator
- CRDL 58.60
- PGP 70.18
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.